The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of biweekly capecitabine and the histone deacetylase inhibitors (HDACi) vorinostat in advanced breast cancer (BC).
M. M. Abu-Khalaf
Research Funding - Roche/Genentech
T. Kim
No relevant relationships to disclose
G. G. Chung
No relevant relationships to disclose
M. DiGiovanna
No relevant relationships to disclose
S. Radke
No relevant relationships to disclose
D. Cornfeld
No relevant relationships to disclose
L. Harris
No relevant relationships to disclose